Bausch Health Companies Inc. (NYSE:BHC) Expected to Post Quarterly Sales of $2.09 Billion

Analysts forecast that Bausch Health Companies Inc. (NYSE:BHCGet Rating) will report sales of $2.09 billion for the current quarter, according to Zacks. Four analysts have provided estimates for Bausch Health Companies’ earnings, with estimates ranging from $2.01 billion to $2.13 billion. Bausch Health Companies posted sales of $2.10 billion during the same quarter last year, which would indicate a negative year-over-year growth rate of 0.5%. The business is scheduled to issue its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Bausch Health Companies will report full-year sales of $8.45 billion for the current fiscal year, with estimates ranging from $8.31 billion to $8.57 billion. For the next financial year, analysts expect that the business will report sales of $8.76 billion, with estimates ranging from $8.66 billion to $8.85 billion. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Bausch Health Companies.

Bausch Health Companies (NYSE:BHCGet Rating) last released its quarterly earnings data on Wednesday, February 23rd. The company reported $1.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.19. The business had revenue of $2.20 billion during the quarter, compared to analysts’ expectations of $2.21 billion. Bausch Health Companies had a negative return on equity of 649.29% and a negative net margin of 4.89%. The business’s quarterly revenue was down .8% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.33 EPS.

A number of research analysts recently issued reports on the company. Royal Bank of Canada dropped their price target on Bausch Health Companies from $21.00 to $17.00 and set an “outperform” rating on the stock in a research note on Sunday, May 15th. BMO Capital Markets dropped their price target on Bausch Health Companies from $26.00 to $15.00 in a research note on Wednesday, May 11th. StockNews.com downgraded Bausch Health Companies from a “buy” rating to a “hold” rating in a research note on Wednesday, May 11th. TheStreet downgraded Bausch Health Companies from a “c-” rating to a “d+” rating in a research note on Monday, March 28th. Finally, Bank of America dropped their price target on Bausch Health Companies from $25.00 to $12.00 in a research note on Wednesday, May 11th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, Bausch Health Companies currently has an average rating of “Buy” and an average target price of $20.80.

NYSE:BHC opened at $9.93 on Monday. The stock’s 50 day moving average price is $19.66 and its 200 day moving average price is $23.34. The company has a market capitalization of $3.58 billion, a PE ratio of -8.71, a P/E/G ratio of 0.22 and a beta of 1.62. Bausch Health Companies has a 52-week low of $7.80 and a 52-week high of $32.54.

In other news, insider Robert Spurr sold 4,846 shares of the firm’s stock in a transaction that occurred on Tuesday, March 15th. The stock was sold at an average price of $22.20, for a total value of $107,581.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Joseph F. Gordon sold 6,338 shares of the firm’s stock in a transaction that occurred on Tuesday, March 1st. The shares were sold at an average price of $23.82, for a total value of $150,971.16. The disclosure for this sale can be found here. Insiders sold a total of 16,668 shares of company stock valued at $378,570 over the last three months. Insiders own 13.75% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Amplius Wealth Advisors LLC purchased a new position in Bausch Health Companies in the 4th quarter valued at approximately $30,000. Glassman Wealth Services increased its stake in Bausch Health Companies by 71.4% in the 4th quarter. Glassman Wealth Services now owns 1,152 shares of the company’s stock valued at $32,000 after purchasing an additional 480 shares in the last quarter. WASHINGTON TRUST Co purchased a new position in Bausch Health Companies in the 1st quarter valued at approximately $28,000. Creative Financial Designs Inc. ADV increased its stake in Bausch Health Companies by 525.0% in the 1st quarter. Creative Financial Designs Inc. ADV now owns 1,250 shares of the company’s stock valued at $29,000 after purchasing an additional 1,050 shares in the last quarter. Finally, Moors & Cabot Inc. purchased a new position in Bausch Health Companies in the 3rd quarter valued at approximately $228,000. 73.38% of the stock is owned by hedge funds and other institutional investors.

About Bausch Health Companies (Get Rating)

Bausch Health Companies Inc, together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products.

See Also

Get a free copy of the Zacks research report on Bausch Health Companies (BHC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.